Hansa Biopharma Q1: Improved outlook - Redeye

Hansa’s Q1 result includes a positive outlook in 2024 supported by additional countries and the Eurotransplant program. 75% of the European market is now reimbursed. The US pivotal study CinfIdeS is also making enrolment progress, and randomization is on track for completion by mid-2024. We expect further positive share price support.

Länk till analysen i sin helhet: https://www.redeye.se/research/996034/hansa-biopharma-q1-improved-outlook?utm_source=finwire&utm_medium=RSS